Desflurane + Propofol
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Delayed Emergence From Anesthesia
Conditions
Delayed Emergence From Anesthesia
Trial Timeline
Aug 1, 2014 → Dec 1, 2015
NCT ID
NCT02631525About Desflurane + Propofol
Desflurane + Propofol is a approved stage product being developed by Baxter for Delayed Emergence From Anesthesia. The current trial status is completed. This product is registered under clinical trial identifier NCT02631525. Target conditions include Delayed Emergence From Anesthesia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02631525 | Approved | Completed |
| NCT02324283 | Pre-clinical | Active |
Competing Products
8 competing products in Delayed Emergence From Anesthesia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Lemborexant + Placebo | Eisai | Approved | 85 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 32 |
| Belatacept + Calcineurin Inhibitor | Bristol Myers Squibb | Phase 2 | 51 |
| ARGX-117 | Argenx | Phase 2 | 49 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 20 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 72 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 25 |